Mayne Pharma Inc. has recalled 11,364 bottles of Liothyronine Sodium Tablets (25 mcg), a prescription medication used to treat hypothyroidism, because the tablets failed dissolution specifications during testing. This failure means the medication may not dissolve properly in the body, which can prevent the patient from receiving the correct amount of active drug. These 100-count bottles were distributed nationwide within the United States under the Perrigo label. Consumers should contact their healthcare provider to discuss how this recall affects their treatment and to obtain a replacement prescription if necessary.
If the medication does not dissolve according to specifications, it may not be absorbed effectively by the body, potentially leading to under-treatment of thyroid conditions. This could result in symptoms of hypothyroidism returning or worsening, though no specific injuries or adverse events have been reported in this notice.
Healthcare provider consultation and pharmacy refund.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.